| 000 | 01481 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250516031100.0 | ||
| 264 | 0 | _c20111003 | |
| 008 | 201110s 0 0 eng d | ||
| 022 | _a1879-0852 | ||
| 024 | 7 |
_a10.1016/j.ejca.2011.02.013 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAmit, O | |
| 245 | 0 | 0 |
_aBlinded independent central review of progression in cancer clinical trials: results from a meta-analysis. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _cAug 2011 |
||
| 300 |
_a1772-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBias |
| 650 | 0 | 4 |
_aClinical Trials, Phase III as Topic _xmethods |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMedical Audit |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aOdds Ratio |
| 650 | 0 | 4 |
_aRandomized Controlled Trials as Topic _xmethods |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 | _aUnited States |
| 700 | 1 | _aMannino, F | |
| 700 | 1 | _aStone, A M | |
| 700 | 1 | _aBushnell, W | |
| 700 | 1 | _aDenne, J | |
| 700 | 1 | _aHelterbrand, J | |
| 700 | 1 | _aBurger, H U | |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 47 _gno. 12 _gp. 1772-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ejca.2011.02.013 _zAvailable from publisher's website |
| 999 |
_c20699695 _d20699695 |
||